Rxivist logo

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics Against Mycobacterium abscessus Complex Clinical Isolates

By Amit Kaushik, Nicole Ammerman, Nicole M Parrish, Eric Nuermberger

Posted 04 Apr 2019
bioRxiv DOI: 10.1101/597765 (published DOI: 10.1128/AAC.00733-19)

The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the in vitro activity of β-lactam antibiotics against Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activity of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (eight-fold) and cefepime (two-fold), and those of other β-lactams, similar to prior results with avibactam and relebactam.

Download data

  • Downloaded 400 times
  • Download rankings, all-time:
    • Site-wide: 63,365
    • In microbiology: 4,244
  • Year to date:
    • Site-wide: 87,718
  • Since beginning of last month:
    • Site-wide: 105,159

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)